TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21697819

Group type: EXPERIMENTAL
Intervention: Functional yogurt NY-YP901 (150 ml, twice a day for 8 weeks)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo yogurt (twice a day for 8 weeks)
Number of subjects: 101
Study: 20205020

Group type: EXPERIMENTAL
Intervention: Implementation intentions and SMS
Number of subjects: 155

Group type: COMPARATOR
Intervention: Implementation intention
Number of subjects: 155

Group type: COMPARATOR
Intervention: SMS
Number of subjects: 155

Group type: COMPARATOR
Intervention: Control groups
Number of subjects: 155
Study: 16889444

Group type: EXPERIMENTAL
Intervention: Olanzapine/fluoxetine combination (OFC) 6/25, 6/50, 12/25, or 12/50 mg/day
Number of subjects: 205

Group type: COMPARATOR
Intervention: Lamotrigine titrated to 200 mg/day
Number of subjects: 205
Study: 14748761

Group type: EXPERIMENTAL
Intervention: Vinorelbine (VNR)
Number of subjects: 2441

Group type: COMPARATOR
Intervention: Control (other chemotherapeutic agents)
Number of subjects: 2441
Study: 11251135

Group type: EXPERIMENTAL
Intervention: Preemptive multimodal analgesia (IV ketorolac 30 mg, intra-articular ropivacaine 0.25% + morphine 2 mg + epinephrine 1:200,000, femoral nerve block with ropivacaine 0.25%) administered 15 minutes before skin incision
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (multimodal analgesia administered immediately after skin closure)
Number of subjects: 40
Study: 9264765

Group type: EXPERIMENTAL
Intervention: Contact laser technique
Number of subjects: 100

Group type: COMPARATOR
Intervention: Non-contact laser technique
Number of subjects: 100
Study: 1606393

Group type: EXPERIMENTAL
Intervention: Growth hormone (1.2 U/kg/week)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 3886395

Group type: EXPERIMENTAL
Intervention: Paracetamol 1000 mg plus codeine 60 mg
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Paracetamol 500 mg plus codeine 30 mg
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study: 29454501

Group type: EXPERIMENTAL
Intervention: Nutricia preOp® (800 ml on the night before surgery/400 ml 2-3 h preoperatively)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo (800 ml on the night before surgery/400 ml 2-3 h preoperatively)
Number of subjects: 32
Study: 29032700

Group type: EXPERIMENTAL
Intervention: Community Engagement and Planning (CEP)
Number of subjects: 504

Group type: COMPARATOR
Intervention: Resources for Services (RS)
Number of subjects: 504
Study: 25628268

Group type: EXPERIMENTAL
Intervention: PC+bevacizumab
Number of subjects: 1345

Group type: COMPARATOR
Intervention: PC
Number of subjects: 1345
Study: 25402403

Group type: EXPERIMENTAL
Intervention: MyFitnessPal app (6 months)
Number of subjects: 212

Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 212
Study: 22657252

Group type: EXPERIMENTAL
Intervention: Lanthanum carbonate oral powder (1000 mg, 3000 mg/d for 10 doses)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Lanthanum carbonate chewable tablet (1000 mg, 3000 mg/d for 10 doses)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Both formulations (oral powder and chewable tablet)
Number of subjects: 72
Study: 20212200

Group type: EXPERIMENTAL
Intervention: Phacoemulsification alone
Number of subjects: 123

Group type: COMPARATOR
Intervention: Combined phacotrabeculectomy
Number of subjects: 123

Group type: COMPARATOR
Intervention: Phacoemulsification alone vs Combined phacotrabeculectomy
Number of subjects: 123
Study: 18849849

Group type: EXPERIMENTAL
Intervention: Systemic antibiotics (AP)
Number of subjects: 77

Group type: COMPARATOR
Intervention: No antibiotics (NP)
Number of subjects: 77
Study: 15956987

Group type: EXPERIMENTAL
Intervention: Divalproex
Number of subjects: 372

Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 372

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 372
Study: 11817468

Group type: EXPERIMENTAL
Intervention: 15% carbamide peroxide bleaching agent with reservoirs
Number of subjects: 0

Group type: COMPARATOR
Intervention: 15% carbamide peroxide bleaching agent without reservoirs
Number of subjects: 0
Study: 10072242

Group type: EXPERIMENTAL
Intervention: Adjusted-dose warfarin therapy (international normalized ratio 2.0 to 3.0)
Number of subjects: 0
Study: 8590744

Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Thrombolytic or angioplasty therapy
Number of subjects: 0
Study: 2405738

Group type: EXPERIMENTAL
Intervention: Enflurane
Number of subjects: 17201

Group type: EXPERIMENTAL
Intervention: Fentanyl
Number of subjects: 17201

Group type: EXPERIMENTAL
Intervention: Halothane
Number of subjects: 17201

Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 17201

Group type: EXPERIMENTAL
Intervention: Preanesthetic medication
Number of subjects: 17201

Group type: COMPARATOR
Intervention: No preanesthetic medication
Number of subjects: 17201
Study: 511251

Group type: EXPERIMENTAL
Intervention: Formolized KFD virus vaccine (two doses administered to 1405 individuals)
Number of subjects: 1989

Group type: COMPARATOR
Intervention: Unvaccinated individuals (584 individuals)
Number of subjects: 1989

Group type: EXPERIMENTAL
Intervention: Formolized KFD virus vaccine
Number of subjects: 1989

Group type: COMPARATOR
Intervention: Unvaccinated individuals
Number of subjects: 1989
Study: 31035949

Group type: EXPERIMENTAL
Intervention: Local excision (LE)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Total mesorectal excision (TME)
Number of subjects: 0
Study: 28107853

Group type: EXPERIMENTAL
Intervention: Clinical Pilates exercises (3 times per week for 6 weeks)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no intervention, usual daily activities)
Number of subjects: 40
Study: 26051567

Group type: EXPERIMENTAL
Intervention: Inhalation aromatherapy with 2% lavender essential oil for 20 min
Number of subjects: 60

Group type: COMPARATOR
Intervention: Distilled water (placebo)
Number of subjects: 60
Study: 24016218

Group type: EXPERIMENTAL
Intervention: Vitamin B12 fortified food (1.4 μg/day)
Number of subjects: 351

Group type: COMPARATOR
Intervention: Control (no complementary food)
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: Intervention
Number of subjects: 351
Study: 21235333

Group type: EXPERIMENTAL
Intervention: Systemic antimicrobials (500 mg amoxicillin + 250 mg metronidazole; three times a day for 10 days)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 19660681

Group type: EXPERIMENTAL
Intervention: CNS prophylaxis during initial treatment for aggressive NHL
Number of subjects: 0

Group type: COMPARATOR
Intervention: Current practice variations in CNS prophylaxis
Number of subjects: 0
Study: 17339867

Group type: EXPERIMENTAL
Intervention: Tolterodine 2 mg twice daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tolterodine 4 mg twice daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg once daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15475132

Group type: EXPERIMENTAL
Intervention: Barefoot condition
Number of subjects: 8

Group type: COMPARATOR
Intervention: Shod condition
Number of subjects: 8
Study: 11476020

Group type: EXPERIMENTAL
Intervention: Modified version of Serpientes y Escaleras (Snakes and Ladders) with health messages
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control group (no modified game)
Number of subjects: 300
Study: 9794055

Group type: EXPERIMENTAL
Intervention: Back belt
Number of subjects: 24

Group type: COMPARATOR
Intervention: No back belt (control)
Number of subjects: 24
Study: 8790569

Group type: EXPERIMENTAL
Intervention: Interferon-alpha 2a (2.5 MIU m-2, 5.0 MIU m-2, 10.0 MIU m-2) three times weekly by intramuscular injection for 12-24 weeks
Number of subjects: 238

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Interferon-alpha 2a (2.5 MIU m-2)
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Interferon-alpha 2a (5.0 MIU m-2)
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Interferon-alpha 2a (10.0 MIU m-2)
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Interferon-alpha 2a
Number of subjects: 238
Study: 3185895

Group type: EXPERIMENTAL
Intervention: Cognitive training procedures relevant to right hemisphere mechanisms
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cognitive training procedures relevant to left hemisphere mechanisms
Number of subjects: 0
Study: 30503831

Group type: EXPERIMENTAL
Intervention: Short-term intensive insulin therapy (IIT) consisting of basal detemir and premeal insulin aspart
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Short-term intensive insulin therapy (IIT)
Number of subjects: 24
Study: 28365377

Group type: EXPERIMENTAL
Intervention: Augmented home exercise programme with Nordic poles
Number of subjects: 61

Group type: COMPARATOR
Intervention: Normal walking (Control)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Augmented home exercise programme (observational cohort)
Number of subjects: 61
Study: 25395350

Group type: EXPERIMENTAL
Intervention: 75 g oral glucose
Number of subjects: 240

Group type: COMPARATOR
Intervention: 100 g standard noodle
Number of subjects: 240
Study: 23664707

Group type: EXPERIMENTAL
Intervention: HAA (homoharringtonine 2 mg/m² per day on days 1-7, cytarabine 100 mg/m² per day on days 1-7, and aclarubicin 20 mg/day on days 1-7)
Number of subjects: 620

Group type: EXPERIMENTAL
Intervention: HAD (homoharringtonine 2 mg/m² per day on days 1-7, cytarabine 100 mg/m² per day on days 1-7, and daunorubicin 40 mg/m² per day on days 1-3)
Number of subjects: 620

Group type: COMPARATOR
Intervention: DA (daunorubicin 40-45 mg/m² per day on days 1-3 and cytarabine 100 mg/m² per day on days 1-7)
Number of subjects: 620

Group type: EXPERIMENTAL
Intervention: HAA
Number of subjects: 620

Group type: EXPERIMENTAL
Intervention: HAD
Number of subjects: 620

Group type: COMPARATOR
Intervention: DA
Number of subjects: 620
Study: 21287804

Group type: EXPERIMENTAL
Intervention: Laparoscopic colectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Open resection
Number of subjects: 0
Study: 18063399

Group type: EXPERIMENTAL
Intervention: LTB019
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 15580349

Group type: EXPERIMENTAL
Intervention: Risedronate (5 mg/day)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Alendronate (70 mg/week)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Both treatments
Number of subjects: 50
Study: 12841703

Group type: EXPERIMENTAL
Intervention: Ergometrine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Oxytocin
Number of subjects: 60
Study: 10498385

Group type: EXPERIMENTAL
Intervention: 500 mg Aspirin
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: 100 mg Pycnogenol
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: 125 mg Pycnogenol
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: 200 mg Pycnogenol
Number of subjects: 57
Study: 8698504

Group type: EXPERIMENTAL
Intervention: Hexavalent PorA outer membrane vesicle vaccine (50 or 100 micrograms)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hexavalent PorA outer membrane vesicle vaccine
Number of subjects: 0
Study: 2069220

Group type: EXPERIMENTAL
Intervention: Bacteriostatic saline flush solution
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sterile saline flush solution
Number of subjects: 0
Study: 6897123

Group type: EXPERIMENTAL
Intervention: 0.5 mg atropine intravenously
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 10 mg pirenzepine intravenously
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 50 mg pirenzepine perorally twice daily for 4 days
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 0.6 mg L-hyoscyamine perorally twice daily for 4 days
Number of subjects: 10
Study: 31742707

Group type: EXPERIMENTAL
Intervention: Intracranial translucency (IT) below the fifth percentile
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Brainstem to brainstem-occipital bone distance (BS/BSOB) above the 95th percentile
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Maxillo-occipital (MO) line abnormality
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Biparietal diameter (BPD) below the fifth percentile
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: BPD to abdominal circumference ratio (BPD/AC) below the fifth percentile
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Aqueduct to occipital bone (AoS) distance below the fifth percentile
Number of subjects: 27
Study: 31513234

Group type: EXPERIMENTAL
Intervention: Vibratory Anesthetic Device ON (VAD ON)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Vibratory Anesthetic Device OFF (VAD OFF)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: VAD ON
Number of subjects: 87
Study: 28679559

Group type: EXPERIMENTAL
Intervention: Diabetes Mellitus (DM)
Number of subjects: 6935

Group type: EXPERIMENTAL
Intervention: Higher hemoglobin A1c in DM subgroup
Number of subjects: 6935

Group type: COMPARATOR
Intervention: Prediabetes Mellitus (pre-DM)
Number of subjects: 6935
Study: 25185521

Group type: EXPERIMENTAL
Intervention: Minimally invasive preperitoneal (MIP) single-layer mesh repair
Number of subjects: 220

Group type: COMPARATOR
Intervention: Lichtenstein hernia repair (LHR)
Number of subjects: 220
Study: 22631626

Group type: EXPERIMENTAL
Intervention: Combined oral midazolam (0.5 mg/kg) and ketamine (3 mg/kg) (MK)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Oral midazolam (1.0 mg/kg) (MS)
Number of subjects: 41

Group type: COMPARATOR
Intervention: No sedative (PS)
Number of subjects: 41
Study: 21482613

Group type: EXPERIMENTAL
Intervention: Video intervention group
Number of subjects: 200

Group type: COMPARATOR
Intervention: In-person counseling group (Control)
Number of subjects: 200
Study: 19492920

Group type: EXPERIMENTAL
Intervention: McDonald cerclage
Number of subjects: 79

Group type: COMPARATOR
Intervention: 17 alpha-hydroxyprogesterone caproate (17OHP-C)
Number of subjects: 79
Study: 16456216

Group type: EXPERIMENTAL
Intervention: OROS-methylphenidate (OROS-MPH)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Immediate-release methylphenidate (IR-MPH)
Number of subjects: 147
Study: 14745639

Group type: EXPERIMENTAL
Intervention: Drink-related visual input
Number of subjects: 7

Group type: COMPARATOR
Intervention: No drink-related visual input
Number of subjects: 7
Study: 11692987

Group type: EXPERIMENTAL
Intervention: Metamizol (1 g intramuscular every 8 hours)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Diclofenac (75 mg intramuscular every 12 hours)
Number of subjects: 166
Study: 9408800

Group type: EXPERIMENTAL
Intervention: Ethanol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Triazolam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8434332

Group type: EXPERIMENTAL
Intervention: intensive, dynamic back‐muscle exercises
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: conventional physiotherapy
Number of subjects: 150

Group type: COMPARATOR
Intervention: placebo-control treatment
Number of subjects: 150
Study: 3303918

Group type: EXPERIMENTAL
Intervention: alpha 2-interferon as an intranasal spray
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 53
Study: 31342228

Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Number of subjects: 1002

Group type: COMPARATOR
Intervention: Low-fat diet
Number of subjects: 1002
Study: 29630112

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided 125I radioactive seed interstitial implantation brachytherapy
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: CT-guided 125I radioactive seed interstitial implantation brachytherapy
Number of subjects: 116

Group type: COMPARATOR
Intervention: Control group (external radiation, systemic chemotherapy or conservative treatment)
Number of subjects: 116
Study: 27647071

Group type: COMPARATOR
Intervention: rhGM‐CSF gel
Number of subjects: 366
Study: 23881309

Group type: EXPERIMENTAL
Intervention: internet-delivered acceptance and commitment therapy (iACT)
Number of subjects: 67

Group type: COMPARATOR
Intervention: internet-delivered cognitive behavior therapy (iCBT)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Both iACT and iCBT
Number of subjects: 67
Study: 22964932

Group type: EXPERIMENTAL
Intervention: Respiratory physiotherapy (MH combined with ERCC)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Standard nursing care (Control)
Number of subjects: 49
Study: 20920766

Group type: EXPERIMENTAL
Intervention: OM-85 BV
Number of subjects: 75
Study: 17595451

Group type: EXPERIMENTAL
Intervention: Euthyrox (50 mkg daily) after PEI
Number of subjects: 55

Group type: COMPARATOR
Intervention: PEI alone (control group)
Number of subjects: 55
Study: 15514883

Group type: EXPERIMENTAL
Intervention: Group A: pulp removed before replantation, calcium hydroxide filled in root canals, routine condensation after half a year
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Group B: pulp removed one week after replantation
Number of subjects: 49

Group type: COMPARATOR
Intervention: Group C: pulp removed until pulp disease
Number of subjects: 49
Study: 11230418

Group type: EXPERIMENTAL
Intervention: anti-LPS IgM ELISA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: anti-LPS IgG ELISA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: anti-LPS IgA ELISA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: antiflagellum IgG ELISA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Widal TO test
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Widal TH test
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: anti-serotype Typhi IgM dipstick assay
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IDeaL TUBEX
Number of subjects: 0

Group type: COMPARATOR
Intervention: Widal TO test vs anti-LPS IgM ELISA
Number of subjects: 0
Study: 9764720

Group type: EXPERIMENTAL
Intervention: Nilvadipine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Terazosin
Number of subjects: 12
Study: 8171944

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 30

Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 30
Study: 3064774

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (C)
Number of subjects: 2342

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide + methotrexate + 5-fluorouracil (CMF)
Number of subjects: 2342

Group type: EXPERIMENTAL
Intervention: No systemic treatment (0)
Number of subjects: 2342

Group type: EXPERIMENTAL
Intervention: CMF for 9 months
Number of subjects: 2342

Group type: COMPARATOR
Intervention: Radiotherapy (RT)
Number of subjects: 2342

Group type: EXPERIMENTAL
Intervention: Tamoxifen (TAM) for 1 year
Number of subjects: 2342

Group type: COMPARATOR
Intervention: No further treatment
Number of subjects: 2342
Study: 29513119

Group type: EXPERIMENTAL
Intervention: Shared decision-making (SDM) responses by healthcare professionals (HCPs) as described in a case-study reflection assignment
Number of subjects: 42
Study: 27905916

Group type: EXPERIMENTAL
Intervention: 100 to 250 mg lisdexamfetamine, dispensed daily on site, over an 8-week period
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Counselling as standard care
Number of subjects: 20
Study: 25124303

Group type: EXPERIMENTAL
Intervention: Cocaine self-administration
Number of subjects: 32
Study: 22080588

Group type: EXPERIMENTAL
Intervention: Varenicline 1 mg b.i.d. for 12 weeks
Number of subjects: 659

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 659

Group type: EXPERIMENTAL
Intervention: Varenicline 1 mg b.i.d.
Number of subjects: 659
Study: 20707210

Group type: EXPERIMENTAL
Intervention: Songling Xuemaikang + Shuxuetong + Aspirin enterie coated tablets
Number of subjects: 160

Group type: COMPARATOR
Intervention: Shuxuetong + Aspirin enterie coated tablets
Number of subjects: 160
Study: 18071731

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Full macular translocation (FMT)
Number of subjects: 50
Study: 16437364

Group type: EXPERIMENTAL
Intervention: D(3) radical resection
Number of subjects: 272

Group type: COMPARATOR
Intervention: D(2) radical resection
Number of subjects: 272
Study: 14729236

Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 11306220

Group type: EXPERIMENTAL
Intervention: Vocational education services
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: Group services
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: Greater number of all inpatient services
Number of subjects: 371
Study: 9550511

Group type: EXPERIMENTAL
Intervention: Subacute rehabilitation in a hospital rehabilitation unit
Number of subjects: 251

Group type: COMPARATOR
Intervention: Health services in the municipality (Control)
Number of subjects: 251
Study: 11835076

Group type: EXPERIMENTAL
Intervention: HCTZ plus perindopril 2 mg
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: HCTZ plus perindopril 4 mg
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: HCTZ plus perindopril 8 mg
Number of subjects: 208

Group type: COMPARATOR
Intervention: HCTZ plus placebo
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: HCTZ plus perindopril (combined)
Number of subjects: 208
Study: 3284266

Group type: EXPERIMENTAL
Intervention: Peroral opioid therapy (SO)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Epidural opioid by a conventional tunnelled epidural catheter (CE)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Epidural catheter connected to an implanted injection port (Port)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Epidural techniques (CE and Port)
Number of subjects: 0
Study: 30738711

Group type: EXPERIMENTAL
Intervention: Vicryl Plus sutures (group 1)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Vicryl sutures (group 2)
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Both groups (Vicryl Plus and Vicryl)
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Vicryl Plus sutures
Number of subjects: 320
Study: 30079329

Group type: COMPARATOR
Intervention: Lactulose
Number of subjects: 87

Group type: COMPARATOR
Intervention: L‐ornithine L‐aspartate
Number of subjects: 87

Group type: COMPARATOR
Intervention: Rifaximin
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 87
Study: 27386641

Group type: EXPERIMENTAL
Intervention: Telbivudine Tablet (600 mg, once per day) combined with Jianpi Bushen Recipe (twice per day)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Telbivudine Tablet alone
Number of subjects: 90